» Articles » PMID: 38406978

Managing Gastrointestinal Manifestations in Systemic Sclerosis, a Mechanistic Approach

Overview
Date 2024 Feb 26
PMID 38406978
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Systemic sclerosis (SSc) is a connective tissue disease with heterogeneous presentation. Gastrointestinal (GI) complications of SSc are characterized by esophageal reflux, abnormal motility, and microbiome dysbiosis, which impact patient quality of life and mortality. Preventative therapeutics are lacking, with management primarily aimed at symptomatic control.

Areas Covered: A broad literature review was conducted through electronic databases and references from key articles. We summarize the physiology of gastric acid production and GI motility to provide context for existing therapies, detail the current understanding of SSc-GI disease, and review GI medications studied in SSc. Finally, we explore new therapeutic options. We propose a management strategy that integrates data on drug efficacy with knowledge of disease pathophysiology, aiming to optimize future therapeutic targets.

Expert Opinion: SSc-GI complications remain a challenge for patients, clinicians, and investigators alike. Management presently focuses on treating symptoms and minimizing mucosal damage. Little evidence exists to suggest immunosuppressive therapy halts progression of GI involvement or reverses damage, leaving many unanswered questions about the optimal clinical approach. Further research focused on identifying patients at risk for GI progression, and the underlying mechanism(s) that drive disease will provide opportunities to prevent long-term damage, and significantly improve patient quality of life.

Citing Articles

Efficacy assessment of intravenous immunoglobulin for gastrointestinal involvement in systemic sclerosis using UCLA SCTC GIT: Case-based review.

Neto M, Albuquerque F, Oliveira J, Cadorio M, Salvador M, Santiago T J Scleroderma Relat Disord. 2024; :23971983241273852.

PMID: 39544902 PMC: 11559525. DOI: 10.1177/23971983241273852.


An evaluation of autonomic and gastrointestinal symptoms, and gastric emptying, in patients with systemic sclerosis.

Hughes M, Harrison E, Herrick A, Lal S, McLaughlin J J Scleroderma Relat Disord. 2024; :23971983241288039.

PMID: 39544898 PMC: 11559523. DOI: 10.1177/23971983241288039.

References
1.
Abrahamsson H, Jansson G . Vago-vagal gastro-gastric relaxation in the cat. Acta Physiol Scand. 1973; 88(3):289-95. DOI: 10.1111/j.1748-1716.1973.tb05457.x. View

2.
McNearney T, Sallam H, Hunnicutt S, Doshi D, Chen J . Prolonged treatment with transcutaneous electrical nerve stimulation (TENS) modulates neuro-gastric motility and plasma levels of vasoactive intestinal peptide (VIP), motilin and interleukin-6 (IL-6) in systemic sclerosis. Clin Exp Rheumatol. 2013; 31(2 Suppl 76):140-50. View

3.
Bassotti G, Satta P, Bellini M . Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options. Clin Exp Gastroenterol. 2021; 14:413-428. PMC: 8547593. DOI: 10.2147/CEG.S256364. View

4.
Johanson J, Morton D, Geenen J, Ueno R . Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2007; 103(1):170-7. DOI: 10.1111/j.1572-0241.2007.01524.x. View

5.
McMahan Z, Kulkarni S, Chen J, Chen J, Xavier R, Pasricha P . Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. Nat Rev Rheumatol. 2023; 19(3):166-181. DOI: 10.1038/s41584-022-00900-6. View